Aminolevulinic acid - SonALAsense
Alternative Names: 5-ALA - SonALAsense; 5-Aminolevulinic acid - SonALAsense; SONALA-001Latest Information Update: 14 Jul 2024
At a glance
- Originator SonALAsense
- Developer SonALAsense; The Ivy Brain Tumor Center
- Class Amino acids; Antianaemics; Antineoplastics; Diagnostic agents; Imaging agents; Keto acids; Levulinic acids; Nootropics; Skin disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glioblastoma
- Phase I/II Glioma
- Preclinical Cancer
Most Recent Events
- 31 May 2024 Efficacy and adverse events data from a phase 0/I trial in glioma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 31 May 2024 Efficacy, adverse events and pharmacokinetic data from a phase I/II trial in Glioma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 13 Dec 2023 Interim adverse events and efficacy data from a phase-I/II trial in Glioma released by SonALAsense